Routine amniocentesis for all women over the age of 35 for detecting t
risomy 21 has been the world standard for nearly two decades. It is ba
sed on a calculated tradeoff: the documented increased risk of trisomy
21 with advancing age versus the risk of fetal loss secondary to the
amniocentesis procedure. Recent data suggest that more specific indivi
dual estimates of risk can be made with a combination of maternal age
and serum markers.(1) We have reported a trend towards an increased ri
sk of trisomy 21 with increased parity.(2) Given the uniqueness of our
population-ultra-Orthodox Jewish mothers who have a high rate of deli
very over the age of 35, high parity, and who abstain from prenatal sc
reening and abortion-we had an opportunity to study the interrelation
of age and parity.